Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

536 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The blood coagulation mechanism in multiple myeloma.
Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. Zangari M, et al. Among authors: fink l. Semin Thromb Hemost. 2003 Jun;29(3):275-82. doi: 10.1055/s-2003-40965. Semin Thromb Hemost. 2003. PMID: 12888931 Review.
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G. Zangari M, et al. Among authors: fink l. Br J Haematol. 2004 Sep;126(5):715-21. doi: 10.1111/j.1365-2141.2004.05078.x. Br J Haematol. 2004. PMID: 15327525 Free article. Clinical Trial.
Thrombosis in multiple myeloma.
Zangari M, Elice F, Fink L, Tricot G. Zangari M, et al. Among authors: fink l. Expert Rev Anticancer Ther. 2007 Mar;7(3):307-15. doi: 10.1586/14737140.7.3.307. Expert Rev Anticancer Ther. 2007. PMID: 17338651 Review.
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M, Fink L, Zhan F, Tricot G. Zangari M, et al. Among authors: fink l. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):228-36. doi: 10.1016/j.clml.2011.03.006. Epub 2011 Apr 8. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21575928 Review.
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G. Zangari M, et al. Among authors: fink l. Blood Coagul Fibrinolysis. 2002 Apr;13(3):187-92. doi: 10.1097/00001721-200204000-00003. Blood Coagul Fibrinolysis. 2002. PMID: 11943931 Clinical Trial.
536 results